<DOC>
	<DOCNO>NCT00471146</DOCNO>
	<brief_summary>The purpose study determine whether investigational study drug , AG-013736 , gemcitabine effective first-line treatment advance pancreatic cancer .</brief_summary>
	<brief_title>Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer .</brief_title>
	<detailed_description>This study prematurely discontinue futility 23 January 2009 , base plan interim analysis independent Data Safety Monitoring Board ( DSMB ) find evidence improvement primary endpoint ( survival ) patient treat axitinib gemcitabine compare gemcitabine alone . Enrollment study discontinue .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Pancreatic Ductal</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically cytologically confirm , metastatic locally , advance pancreatic adenocarcinoma amenable curative resection . Adequate renal , hepatic bone marrow function . Performance status 0 1 . Prior treatment systemic chemotherapy metastatic disease . Prior treatment gemcitabine , AG013736 , vascular endothelial growth factor inhibitor . Current recent bleeding , thromboembolic event use thrombolytic agent . Inability take oral medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Randomized Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For Advanced Pancreatic Cancer .</keyword>
</DOC>